NanoViricides Inc. (NNVC)

[NNVClover]

Most people in the drug biz calculate PK as a ng/mL. It's hard to do in animals but in general you need 500-1000ng/mL for an active drug. That is a very fast and loose #.

I was reading the NNVC patent application and on one hand I was disappointed (as a short) that the drugs seem reliable "enough" from a PK perspective. There is probably no 'angle' for me from this perspective.

I was somewhat thrilled to see that the patent application,

http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PG01&s1=diwan&s2=anil&OS=diwan+AND+anil&RS=diwan+AND+anil

, does not really contemplate anything novel. For example, "Example 4" contemplates the attachment of zanamivir to these ligands. A better way to deliver Relenza is not going to be attractive. The rest of the examples are similar and the invention is tautological. If there are ligands which act as anti-virals, the benefit of a polymeric construct to attach those ligands to is useless. Just administer the ligand. This doesn't work for all ligands, I understand, but I'm skeptical that there is anything novel here at all.